Protein degraders eliminate target proteins through different mechanisms. PROTACs are bifunctional molecules that bring a target protein close to an E3 ubiquitin ligase, leading to ubiquitination and proteasomal degradation. Molecular glues stabilize interactions between target proteins and E3 ligases, achieving similar outcomes. Lysosome-directed degraders (LYTACs, AUTACs) route proteins to lysosomes for degradation. All these approaches harness the cell’s natural protein disposal systems.

Preclinical testing is critical for advancing protein degraders, ensuring their safety, efficacy, and clinical viability. DMPK studies address unique challenges such as poor bioavailability, complex metabolism with linker cleavage, and tissue distribution requirements. Bioanalytical testing must overcome low in vivo concentrations due to catalytic mechanisms and track multiple metabolites. Toxicology studies identify potential risks of off-target protein degradation, neo-substrate formation, and immune modulation. These comprehensive assessments are essential for regulatory submissions and clinical translation.

Protein degraders present distinct challenges, including large molecular weight and poor solubility (particularly for bivalent degraders), complex metabolite profiles from linker cleavage, poor permeability limiting bioavailability, the “hook effect” where excess degrader disrupts efficacy, and mechanism-dependent pharmacology requiring measurement of protein depletion rather than just activity inhibition. Additionally, there are no degrader-specific regulatory guidelines, requiring modality-aware approaches to species selection, dose optimization, and safety assessment.

Essential studies include physicochemical characterization in biorelevant media, permeability assessment using Caco-2 and MDR1-MDCK models, metabolic stability across multiple enzyme systems, tissue distribution studies, radiolabeled ADME studies, target protein quantification aligned with PK sampling, proteomics screening for off-target degradation, toxicokinetic integration, and modality-specific checks such as confirming receptor expression for LYTACs/AUTACs or E3 dependency for molecular glues.

Efficacy evaluation focuses on measuring target protein depletion using Western blotting, immunoassays, or mass spectrometry in cell-based systems and tissues. For PROTACs, ternary complex formation between target, degrader, and E3 ligase is confirmed. Molecular glues require demonstration of E3 ligase dependency. Lysosome-directed degraders need validation of receptor engagement and internalization. Downstream functional assessments measure effects on signaling pathways and cellular phenotypes, while dose-response studies map therapeutic windows and identify potential hook effects.

Critical safety assessments include proteomics screening for off-target protein degradation from promiscuous E3 ligase recruitment or neo-substrate formation, cell-based selectivity panels across tissue types, cytokine release and complement activation assays for immune modulation risks, route-specific local tolerance studies, genetic toxicology tailored to linker and warhead chemistry, metabolite characterization for linker-cleaved products, and immunogenicity monitoring. GLP toxicology studies must address species selection based on target protein and E3 ligase homology.

PK studies measure degrader concentrations in plasma and target tissues across multiple routes of administration, using high-sensitivity LC-MS/MS methods or hybrid immuno-capture approaches. Radiolabeled ADME studies track the distribution and excretion of a compound. PD assessments quantify target protein levels over time, correlating protein depletion kinetics with degrader exposure. Dose-ranging studies identify therapeutic windows while avoiding hook effects. Species selection considers both metabolic similarity and conservation of the target/E3 ligase.

In vitro assays provide initial screening for degradation activity, assess solubility in biorelevant media, evaluate permeability and efflux transporter interactions, characterize metabolic stability across hepatocytes and microsomal systems, identify metabolic soft spots and linker cleavage patterns, measure plasma protein binding, and screen for off-target degradation and cytotoxicity across relevant cell lines.

In vitro assays provide initial screening for degradation activity, assess solubility in biorelevant media, evaluate permeability and efflux transporter interactions, characterize metabolic stability across hepatocytes and microsomal systems, identify metabolic soft spots and linker cleavage patterns, measure plasma protein binding, and screen for off-target degradation and cytotoxicity across relevant cell lines.

Animal models evaluate in vivo efficacy through target protein depletion in tissues, establish PK/PD relationships across different routes and dose levels, assess tissue distribution and penetration to target sites, identify hook effect thresholds, and conduct toxicology studies. Species selection requires consideration of target protein conservation, E3 ligase homology, and metabolic similarity to humans.

Regulatory considerations include addressing the absence of degrader-specific FDA or ICH guidelines, providing a mechanistic demonstration of degradation pathway engagement (ternary complex for PROTACs, E3 dependency for molecular glues, receptor-mediated uptake for LYTACs/AUTACs), justifying species selection based on target biology and E3 ligase conservation, explaining dose-response frameworks that account for hook effects and catalytic mechanisms, and integrating data across DMPK, bioanalysis, and toxicology platforms for cohesive IND submissions.

Stability is assessed through blood and plasma stability testing, forced degradation studies under various pH and temperature conditions, and metabolic stability across multiple enzyme systems. Bioavailability is evaluated by measuring degrader concentrations in plasma and tissues after different routes of administration, with particular attention to oral bioavailability challenges from molecular size, poor permeability, and efflux transporter interactions.

Common studies include dose range finding (DRF) to establish tolerability, GLP repeat-dose toxicity in rodents and non-human primates, genetic toxicology tailored to linker and warhead structures, metabolite identification and characterization in plasma, urine, feces and bile, immunogenicity and anti-drug antibody monitoring, and reproductive/carcinogenicity studies. Studies integrate toxicokinetics to correlate exposure with findings.

Target selectivity is evaluated using proteomics approaches to identify unintended protein degradation, cell-based selectivity panels across multiple tissue types, biochemical assays confirming specificity of target and E3 ligase engagement, and functional assays monitoring for adverse effects. For molecular glues, selectivity requires confirming specific E3 ligase dependency and substrate recognition.

Off-target effects include unintended protein degradation from promiscuous E3 ligase recruitment, neo-substrate formation bringing unrelated proteins to the E3 ligase, immune modulation through the ubiquitin-proteasome pathway, and linker metabolite toxicity. These are assessed through unbiased proteomics screening, cell-based cytotoxicity panels, immune function assays, and comprehensive metabolite characterization with independent safety testing of major metabolites.

Degradation efficacy is measured by quantifying target protein depletion using Western blotting, ELISA, or LC-MS/MS-based protein quantification in cells and tissues. Time-course studies establish degradation kinetics and duration of effect. Dose-response curves identify optimal concentrations and detect hook effects. Functional downstream readouts confirm biological consequences of target protein loss.

Key considerations include optimizing binding affinity to target and E3 ligase (for PROTACs), ensuring appropriate linker length and stability, improving cell permeability and tissue distribution, minimizing off-target degradation through selective E3 recruitment, addressing formulation challenges from poor solubility, and establishing PK/PD relationships that account for catalytic mechanisms and potential hook effects.

For PROTACs: the target-binding ligand, E3 ligase-binding ligand, and linker must each be evaluated for efficacy, stability, selectivity, and safety. For molecular glues: target engagement, E3 ligase interaction, and selectivity profile. For LYTACs/AUTACs: receptor-binding domain, target-binding domain, and confirmation of receptor expression and internalization pathways. Each component requires independent characterization and evaluation as part of the complete degrader.

Linker design impacts stability, degradation efficacy, permeability, and metabolic profile. Effective linker design ensures optimal geometry for ternary complex formation in PROTACs while maintaining stability against premature cleavage. Linker metabolism generates multiple metabolites requiring tracking and characterization. Molecular architecture affects solubility, formulation approaches, bioavailability, and tissue penetration, with bivalent degraders presenting greater challenges than molecular glues or lysosome-directed approaches.